These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28605493)

  • 1. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study.
    Nozza S; Malagoli A; Maia L; Calcagno A; Focà E; De Socio G; Piconi S; Orofino G; Cattelan AM; Celesia BM; Gervasi E; Guaraldi G;
    J Antimicrob Chemother; 2017 Oct; 72(10):2879-2886. PubMed ID: 28605493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years.
    Guaraldi G; Malagoli A; Calcagno A; Mussi C; Celesia BM; Carli F; Piconi S; De Socio GV; Cattelan AM; Orofino G; Riva A; Focà E; Nozza S; Di Perri G
    BMC Geriatr; 2018 Apr; 18(1):99. PubMed ID: 29678160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPO" Cohort.
    Focà E; Magro P; Guaraldi G; Riva A; Cattelan AM; De Socio GV; Costa C; Piconi S; Celesia BM; Nozza S; Orofino G; Castagna A; Di Perri G; Castelli F; Calcagno A;
    PLoS One; 2019; 14(10):e0222225. PubMed ID: 31622347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany.
    Lopes S; O'Day K; Meyer K; Van Stiphout J; Punekar Y; Radford M; Haas JS
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):270-278. PubMed ID: 31950545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of polypharmacy on antiretroviral prescription in people living with HIV.
    Guaraldi G; Menozzi M; Zona S; Calcagno A; Silva AR; Santoro A; Malagoli A; Dolci G; Mussi C; Mussini C; Cesari M; Khoo SH
    J Antimicrob Chemother; 2017 Feb; 72(2):511-514. PubMed ID: 27834193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
    Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
    J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Decline in HIV-1 Drug Resistance in Heavily Antiretroviral-Experienced Patients Is Associated with Optimized Prescriptions in a Treatment Roll-Out Program in Mexico.
    Calva JJ; Larrea S; Tapia-Maltos MA; Ostrosky-Frid M; Lara C; Aguilar-Salinas P; Rivera H; Ramírez JP
    AIDS Res Hum Retroviruses; 2017 Jul; 33(7):675-680. PubMed ID: 28094565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
    Viganò A; Mora S; Giacomet V; Stucchi S; Manfredini V; Gabiano C; Salvini F; Cellini M; Tamburrini E; Puzzovio M; Zuccotti GV
    Antivir Ther; 2011; 16(8):1259-66. PubMed ID: 22155907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.
    Holtzman C; Armon C; Tedaldi E; Chmiel JS; Buchacz K; Wood K; Brooks JT;
    J Gen Intern Med; 2013 Oct; 28(10):1302-10. PubMed ID: 23605401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).
    Reinheimer C; Wesner A; Keppler OT; Doerr HW; Herrmann E; Stürmer M; Stephan C
    Med Microbiol Immunol; 2016 Aug; 205(4):315-20. PubMed ID: 26746222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
    Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic.
    Grant-McAuley W; Fogel JM; Galai N; Clarke W; Breaud A; Marzinke MA; Mbwambo J; Likindikoki S; Aboud S; Donastorg Y; Perez M; Barrington C; Davis W; Kerrigan D; Eshleman SH
    PLoS One; 2020; 15(10):e0240890. PubMed ID: 33119663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.